Emergent BioSolutions
EBS
#7882
Rank
A$0.56 B
Marketcap
A$10.93
Share price
-0.52%
Change (1 day)
3.20%
Change (1 year)

P/E ratio for Emergent BioSolutions (EBS)

P/E ratio as of July 2026 (TTM): 5.43

According to Emergent BioSolutions 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 5.42553. At the end of 2025 the company had a P/E ratio of 13.0.

P/E ratio history for Emergent BioSolutions from 2007 to 2026

PE ratio at the end of each year

Year P/E ratio Change
202513.0-594.02%
2024-2.631533.19%
2023-0.1613-93.88%
2022-2.64-126.26%
202110.0-35.24%
202015.5-69.54%
201950.97.32%
201847.499%
201723.8-16.55%
201628.613.48%
201525.2-11.29%
201428.46.11%
201326.78.33%
201224.7

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Pfizer
PFE
19.0 250.90%๐Ÿ‡บ๐Ÿ‡ธ USA
Merck
MRK
35.5 554.18%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
13.1 140.83%๐Ÿ‡ฌ๐Ÿ‡ง UK
Soligenix
SNGX
-0.1124-102.07%๐Ÿ‡บ๐Ÿ‡ธ USA
SIGA Technologies
SIGA
8.52 57.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Celldex Therapeutics
CLDX
-9.17-268.96%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
22.9 321.77%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.